The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Escitalopram, the active (S)-enantiomer of citalopram, has been approved in many countries throughout the world for the treatment of depression and anxiety disorders. It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and muscarinic receptors. Escitalopram has favourable pharmacokinetics: it is rapidly absorbed, has a bioavailability of 80% and is not affected by food intake. It has little potential for drug interactions: it has low protein binding and, as it is metabolised by three CYP isozymes, any impairment in the activity of one is unlikely to have a significant effect on metabolic clearance. Caution is necessary only when it is coadministered with drugs metabolised by CYP2D6, such as metoprolol, or administered to the elderly or patients with severe hepatic or renal impairment. The multiple-dose pharmacokinetics of oral escitalopram are proportional at a range of doses including its therapeutic doses. Escitalopram is approved for the treatment of a number of anxiety disorders. It seems to be well tolerated and induces few or no discontinuation symptoms, and may be considered a first-line agent for the pharmacotherapy of obsessive-compulsive disorder, generalised anxiety disorder, panic disorder and social phobia. Further studies are needed to define its activity in impulse control disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Pharmacokinetics of Escitalopram
Rao, N. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746040-00002 · Cited by 256
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178 · cited 1×
“Another randomised double-blind trial comparing escitalopram and venlafaxine at the highest doses recommended in the US (20 mg/day and 225 mg/day, respectively) in depressed out-patients reported that, when titrated rapidly to the maximum recommended dose, escitalopram was at least as effective as venlafaxine, and sig…”
BackgroundMontgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Discontinuation symptoms in depression and anxiety disorders
Baldwin, D. S., Montgomery, S. A., Nil, R., & Lader, M. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705006358 · Cited by 140 · cited 1×
“There were no differences in the discontinuation symptoms following the administration of each antidepressant in the three diagnostic groups and no evidence indicating a higher incidence of symptom with increased length of treatment [83] .”
BackgroundMontgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram
Lundberg, J., Christophersen, J. S., Petersen, K. B., Loft, H., Halldin, C., & Farde, L. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007486 · Cited by 55
Escitalopram: A Review of its Use in the Management of Anxiety Disorders
Dhillon, S., Scott, L. J., & Plosker, G. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00010 · Cited by 47
Metadata
- Authors
- Bareggi, S. R., Mundo, E., Dell'Osso, B., & Altamura, A. C.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2007-10
- Volume
- 3
- Issue
- 5
- Pages
- 741-753
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2119000485
- Cited by
- 178
- References
- 9
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. https://app.cochat.ai/papers/10.1517/17425225.3.5.741
- The paper
- Bareggi, S. R., Mundo, E., Dell'Osso, B., & Altamura, A. C. (2007). The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425225.3.5.741
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.